Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages

Annals of Clinical Microbiology and Antimicrobials

Volumn 13, Issue 1, 2014, Pages

  Molina Torres, Carmen A ^a   Barba Marines, Alejandra ^a   Valles Guerra, Orestes ^a   Ocampo Candiani, Jorge ^a   Cavazos Rocha, Norma ^a   Pucci, Michael J ^b   Castro Garza, Jorge ^c   Vera Cabrera, Lucio ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b Achillion Pharmaceuticals Inc   (United States)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

ACH 702; Oxazolidinones; Tuberculosis

Indexed keywords

ACH 702; ANTIBIOTIC AGENT; MOXIFLOXACIN; NANOPARTICLE; QUINOLONE DERIVATIVE; RIFAMPICIN; TEDIZOLID; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; INTRACELLULAR KILLING; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTITUBERCULAR AGENTS; BACTERIAL LOAD; CELL LINE; HUMANS; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; ORGANOPHOSPHATES; OXAZOLES; QUINOLONES; THIAZOLES;

EID: 84897963171     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-13-13     Document Type: Article

References (24)

1. Tuberculosis Fact Sheet No. 104. 2013, Available from: http://www.who.int/mediacentre/factsheets/fs104/en/index.html.
2. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008, 52:4442-4447. 10.1128/AAC.00859-08, 2592863, 18838596.
3. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013, 309:559-569. 10.1001/jama.2013.241, 23403680.
4. Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. Antimicrob Agents Chemother 2007, 51:1259-1267. 10.1128/AAC.01315-06, 1855488, 17242152.
5. Wang Q, Lucien E, Hashimoto A, Pais GC, Nelson DM, Song Y, Thanassi JA, Marlor CW, Thoma CL, Cheng J, Podos SD, Ou Y, Deshpande M, Pucci MJ, Buechter DD, Bradbury BJ, Wiles JA. Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J Med Chem 2007, 50:199-210. 10.1021/jm060844e, 17228862.
6. Wiles JA, Song Y, Wang Q, Lucien E, Hashimoto A, Cheng J, Marlor CW, Ou Y, Podos SD, Thanassi JA, Thoma CL, Deshpande M, Pucci MJ, Bradbury BJ. Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: in vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett 2006, 16:1277-1281. 10.1016/j.bmcl.2005.11.064, 16337789.
7. Molina-Torres CA, Ocampo-Candiani J, Rendón A, Pucci MJ, Vera-Cabrera L. In vitro activity of a new Isothiazoloquinolone (ACH-702) against Mycobacterium tuberculosis and other mycobacteria. Antimicrob Agents Chemother 2010, 54:2188-9210. 10.1128/AAC.01603-09, 2863650, 20231398.
8. Vera-Cabrera L, Gonzalez E, Rendon A, Ocampo-Candiani J, Welsh O, Velazquez-Moreno VM, Choi SH, Molina-Torres C. In vitro activities of DA-7157 and DA-7218 against mycobacterium tuberculosis and nocardia brasiliensis. Antimicrob Agents Chemother 2006, 50:3170-3172. 10.1128/AAC.00571-06, 1563545, 16940121.
9. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002, 46:2723-2726. 10.1128/AAC.46.8.2723-2726.2002, 127358, 12121967.
10. Haerian H, McHugh P, Brown R, Somes G, Solomon SS. Gatifloxacin produces both hypoglycemia and hyperglycemia: a retrospective study. Am J Med Sc 2008, 335:95-98.
11. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005, 172:1487-1490. 10.1164/rccm.200504-613PP, 2718451, 16151040.
12. Bala I, Hariharan S, Ravi Kumar MNV. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004, 21:387-422. 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20, 15719481.
13. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. Rapid, low-technology MIC determination with clinical mycobacterium tuberculosis isolates by using the microplate alamar blue assay. J Clin Microbiol 1998, 36:362-366. 104543, 9466742.
14. Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr C, Hoffman M, Maincent P. Biodegradable monodispersed nanoparticles prepared by pressure homogenisation-emulsification. Int J Pharm 1999, 184:97-105. 10.1016/S0378-5173(99)00107-6, 10425355.
15. Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother 2006, 57:1146-1152. 10.1093/jac/dkl128, 16597631.
16. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003, 83:373-378. 10.1016/j.tube.2003.07.001, 14623168.
17. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004, 24:599-604. 10.1016/j.ijantimicag.2004.07.010, 15555884.
18. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem 1986, 159:109-113. 10.1016/0003-2697(86)90314-3, 3812988.
19. Castro-Garza J, Barrios-García HB, Cruz-Vega DE, Said-Fernández S, Carranza-Rosales P, Molina-Torres CA, Vera-Cabrera L. Use of a colorimetric assay to measure differences in cytotoxicity of Mycobacterium tuberculosis strains. J Med Microbiol 2007, 56:733-737. 10.1099/jmm.0.46915-0, 17510256.
20. Castro-Garza J, Luna-Herrera J, Barrios-García HB, de Paz-Palacios I. Actividad antituberculosis en macrófagos infectados con Mycobacterium tuberculosis. Manual De Técnicas De Bioevaluación De Nuevos Agentes Antituberculosis 2006, 129-137. Spain: Proyecto X.11 (CYTED), Said-Fernández S, del Olmo Fernández E, Leal Garza C, San Feliciano A.
21. Clinical trials, gov Controlled Comparison Of Two Moxifloxacin Containing Treatment Shortening Regimens In Pulmonary Tuberculosis. (REMoxTB). March 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00864383?term.moxifloxacin&rank.1.1. Accessed April 20, 2012, Clinical trials, gov.
22. Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189. 10.1016/S0140-6736(09)60333-0, 2866651, 19345831.
23. Shegokar R, Al Shaal L, Mitri K. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci 2011, 14:100-116. Review.
24. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70:1-20. 10.1016/S0168-3659(00)00339-4, 11166403.